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AbstrACt
Introduction Dopamine dysregulation has been 
identified as a key modulator of behavioural impairment 
in neurofibromatosis type 1 (NF1) and a potential 
therapeutic target. Preclinical research demonstrates 
reduced dopamine in the brains of genetically engineered 
NF1 mouse strains is associated with reduced spatial-
learning and attentional dysfunction. Methylphenidate, a 
stimulant medication that increases dopaminergic and 
noradrenergic neurotransmission, rescued the behavioural 
and dopamine abnormalities. Although preliminary clinical 
trials have demonstrated that methylphenidate is effective 
in treating attention deficit hyperactivity disorder (ADHD) 
symptoms in children with NF1, its therapeutic effect on 
cognitive performance is unclear. The primary aim of this 
clinical trial is to assess the efficacy of methylphenidate 
for reducing attention deficits, spatial working memory 
impairments and ADHD symptoms in children with NF1.
Methods and analysis A randomised, double-blind, 
placebo-controlled trial of methylphenidate with a two 
period crossover design. Thirty-six participants with 
NF1 aged 7–16 years will be randomised to one of two 
treatment sequences: 6 weeks of methylphenidate 
followed by 6 weeks of placebo or; 6 weeks of placebo 
followed by 6 weeks of methylphenidate. Neurocognitive 
and behavioural outcomes as well as neuroimaging 
measures will be completed at baseline and repeated 
at the end of each treatment condition (week 6, week 
12). Primary outcome measures are omission errors on 
the Conners Continuous Performance Test-II (attention), 
between-search errors on the Spatial Working Memory 
task from the Cambridge Neuropsychological Test 
Automated Battery (spatial working memory) and the 
Inattentive and Hyperactivity/Impulsivity Symptom 
Scales on the Conners 3-Parent. Secondary outcomes 
will examine the effect of methylphenidate on executive 
functions, attention, visuospatial skills, behaviour, fine-
motor skills, language, social skills and quality of life.
Ethics and dissemination This trial has hospital ethics 
approval and the results will be disseminated through 
peer-reviewed publications and international conferences.
trial registration number ACTRN12611000765921.
IntroduCtIon
Neurofibromatosis type 1 (NF1) is an auto-
somal dominant disorder that is caused by 
a diverse range of loss-of-function mutations 
in the NF1 gene, which resides on chromo-
some 17q11.2. With a birth incidence of 1 in 
2700, NF1 is one of the most common mono-
genic disorders affecting cognitive function.1 
The NF1 gene encodes the protein neurofi-
bromin, a tumour suppressor that is a negative 
regulator of Ras2 and a positive regulator of 
dopamine (DA) homeostasis.3 Loss of neuro-
fibromin expression results in increased 
Ras activity and cell growth.4 Diagnostic 
features include alterations in skin pigmen-
tation (café au lait spots, skinfold freckling), 
Lisch nodules and nervous system tumours 
strengths and limitations of this study
 ► This is the first randomised controlled trial evaluat-
ing the effects of methylphenidate in the treatment 
of cognitive deficits in neurofibromatosis type 1 
(NF1).
 ► This study is adequately powered to provide a clini-
cally meaningful outcome.
 ► The cognitive primary outcome measures are analo-
gous to methylphenidate-responsive tests previous-
ly used in NF1 mouse models, assessing sustained 
attention and spatial working memory.
 ► A multimodal approach including event-related and 
resting state functional neuroimaging will inves-
tigate the effects of methylphenidate on neurobi-
ological processes in NF1 and how these relate to 
cognitive and behavioural changes.
 ► A 6-week intervention period may not be sufficient to 
see the full impact of treatment on daily functioning 
and quality of life; open-label extension studies will 
be required to determine these long-term effects.
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(neurofibromas and optic pathway gliomas).5 While 
typically regarded as a cancer predisposition syndrome, 
the most common complication of NF1 in childhood is 
impairment in academic achievement and cognition, 
with attentional, executive, language and visuospatial 
functions frequently affected.6–9 Attentional problems 
are one of the most commonly reported impairments, 
with up to 70% of children displaying deficits in one or 
more aspects of the attention system (sustained, selective, 
divided and shifting attention).6 10 11 Significant executive 
impairments are also reported, including problems with 
working memory and inhibitory control.12–14 The NF1 
cognitive phenotype has many similarities to that seen 
in children with attention deficit hyperactivity disorder 
(ADHD) and over one-third of children with NF1 meet 
diagnostic criteria for ADHD.14–16 Like children with idio-
pathic ADHD, where dissociations between cognition 
and symptoms have been established,17 18 disruption to 
attentional and executive functions are not tightly bound 
to clinical symptoms, with commensurate cognitive defi-
cits occurring in children with NF1 irrespective of ADHD 
comorbidity.12 16 Functional MRI (fMRI) studies in chil-
dren with NF1 reveal disturbances within neural networks 
associated with working memory,19 inhibitory control20 
and attention,21 which further resemble findings in chil-
dren with idiopathic ADHD.22–26 In particular, hypoacti-
vation in prefrontal regions,19 20 striatum19 and anterior 
cingulate cortex21 have been identified as loci of neuro-
biological dysfunction in NF1. Critically, executive and 
attentional deficits, as well as ADHD symptoms, signifi-
cantly impact the scholastic abilities16 and social compe-
tence27 28 of children with NF1, highlighting them as key 
clinical targets for therapeutic intervention.
Various genetically engineered Nf1 mouse strains have 
successfully modelled the cognitive and behavioural 
deficits seen in children with the disorder, enabling 
investigation into the underlying pathophysiology and 
identification of new therapeutic drug targets. Mice with 
a heterozygous inactivating mutation in the NF1 gene 
(Nf1+/-) demonstrate Ras signalling-dependent increases 
in gamma-aminobutyric acid in the brain.29 Spatial 
learning and attention impairments have been associated 
with elevated Ras signalling and inhibition of Ras trans-
forming activity with lovastatin has rescued the behavioural 
phenotype in Nf1 mice.30 Despite the significant promise, 
human randomised controlled trials (RCTs) using statins 
have demonstrated poor efficacy, with limited treatment 
effects on cognitive outcomes.31–33
Convergent mouse and human data also indicate that 
reduced neurofibromin expression can lead to dysreg-
ulated neuronal DA levels, which may contribute to the 
observed attentional and learning impairments in chil-
dren with NF1.34–37 Nf1+/- mice with bi-allelic inactivation of 
Nf1 in GFAP+ astroglial cells display reduced exploratory 
behaviours, attention abnormalities36 and spatial learning 
deficits.35 These behavioural deficits have been linked 
to a presynaptic DA defect in the striatum36 and hippo-
campus.35 In vivo experiments using positron emission 
tomography imaging with 11C-raclopride have extended 
these research findings demonstrating increased stri-
atal binding, consistent with abnormally low DA levels.34 
Treatment with methylphenidate (MPH), a stimulant 
medication that increases extracellular DA availability by 
inhibiting its reuptake by the DA transporter, corrected 
mice behavioural abnormalities and restored the DA 
levels in the striatum and hippocampus.34–36 These find-
ings, which link NF1 gene expression, DA dysregulation 
and attention deficits provide a robust foundation for the 
evaluation of DA reuptake inhibitors such as MPH as a 
potential treatment for both cognitive and behavioural 
deficits in children with NF1.
In idiopathic ADHD studies, MPH is effective at 
reducing ADHD symptoms with a large effect size (0.8–
1.0).38 39 fMRI studies in ADHD participants indicate that 
acute doses of MPH upregulate and normalise under 
functioning brain regions in ADHD, including the basal 
ganglia and prefrontal cortex.40 41 While the effects of 
MPH on cognition in ADHD are less clearly understood, a 
meta-analysis of 36 studies reported significantly improved 
executive memory, non-executive memory, reaction time, 
reaction time variability and response inhibition in MPH 
versus placebo conditions, although with smaller effect 
sizes than those reported for ADHD symptoms.42
Clinical trials of MPH in NF1 are limited. An open-
label uncontrolled trial of MPH conducted in 20 chil-
dren with NF1 who met diagnostic criteria for ADHD 
suggested improved performance on a computer-
ised task of attention and corresponding gains on 
informant-reported behaviour (attention, anxiety/
depression and social competence) across a 12-month 
treatment period.14 The only other clinical trial evalu-
ating the effects of MPH in children with NF1 reported 
beneficial effects of MPH in reducing parent-reported 
ADHD symptoms in children with NF1 following 4 
weeks of treatment.43 Despite the preclinical evidence 
that DA-targeted therapies may improve cognitive defi-
cits in children with NF1, there are no published RCTs 
evaluating the effect of MPH on cognitive outcomes in 
this population.
MEthods And AnAlysIs
study aims
The primary aim of this study is to determine the efficacy 
of MPH at improving sustained attention, spatial working 
memory and ADHD symptoms in children with NF1. The 
secondary aim is to evaluate the effects of MPH on visu-
ospatial learning, executive functioning, other aspects of 
attention, expressive language, social skills, fine-motor 
skills, quality of life and behaviour.
Exploratory aims of the study are to examine the asso-
ciations between MPH-related changes in the various 
aspects of cognition and changes in ADHD symptoms. We 
will also explore the effect of MPH on functional brain 
activity in children with NF1 and relate this to improve-
ments in cognitive and behavioural function.
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study design and setting
A phase II, multicentre, randomised, double-blind, 
placebo-controlled clinical trial with a two period cross-
over design. Participants will be randomised to sequence 
A (6 weeks of MPH followed by 6 weeks of placebo) or 
sequence B (6 weeks of placebo followed by 6 weeks of 
MPH). Cognitive testing, behavioural outcomes and 
neuroimaging be completed by participants at baseline 
and at the end of each treatment condition. Figure 1 
provides an overview of the study.
study procedures
Prospective participants will be recruited from outpa-
tient NF1 clinics at The Children’s Hospital at Westmead 
(CHW) in Sydney and The Royal Children’s Hospital 
in Melbourne, Australia. Children are referred to these 
clinics by general practitioners and medical specialists for 
evaluation, diagnosis and management of NF1. Partici-
pant recruitment will take place via the following methods: 
(1) families of patients attending NF1 clinics will be asked 
whether they would be willing to hear more about the 
trial, (2) mailing information packages to families that 
attend the clinics and (3) online announcements on the 
Australian Children’s Tumour Foundation website. The 
research team will contact families interested in partici-
pating and provide further study information and address 
any questions about the trial. Those willing to participate 
will be asked to provide written informed consent.
Screening and eligibility
Eligibility will be checked at a preliminary screening 
appointment (see 'Inclusion criteria' and 'Exclusion 
criteria' sections below). At this visit, the site physician 
will collect a detailed medical history including an intake 
interview with questions aimed to identify eligibility of 
the participant. The physician will also conduct a phys-
ical examination to confirm NF1 diagnosis and docu-
ment height, weight, blood pressure, pulse rate and 
head circumference. Baseline adverse effects will be 
documented, allowing us to determine whether subse-
quently endorsed adverse effects are related to study 
medication. All participants will complete a screen for 
cardiac abnormalities (ECG), and eligible females will 
complete a urine pregnancy test. Concomitant medi-
cations taken by the participant at commencement of 
the trial will be documented. Parents/caregivers of all 
participants will undergo a structured interview using 
the Mini International Neuropsychiatric Interview for 
Children and Adolescents (MINI-Kid) to screen for 
psychological disorders and substance abuse.44 Parents/
caregivers will also complete the Conners 3-Parent45 to 
identify the nature and severity of ADHD symptoms at 
baseline. The study psychologist will determine whether 
the participant satisfies cognitive-based entry criteria by 
administering the Conners Continuous Performance 
Test II (CPT II) (sustained attention),46 Cambridge 
Neuropsychological Test Automated Battery  Spatial 
Working Memory (CANTAB SWM)47 and the Wechsler 
Abbreviated Scale of Intelligence (WASI; IQ).48 If the 
participant has completed an IQ test within 12 months 
of screening, then the WASI will not be administered and 
the previous score will be used. Examples of acceptable 
IQ tests include the WASI, Wechsler Intelligence Scale 
Figure 1 Flow diagram of participant allocation.
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for Children—Fourth Edition49 or Fifth Edition50 and the 
Stanford-Binet Intelligence Scales Fifth Edition.51 Partici-
pants will be informed of the potential risks and benefits 
of participating, the aim of the study and that participa-
tion is voluntary. The first participant was randomised to 
study on 30 July 2011 and we anticipate the end date for 
enrolment to be December 2019.
Inclusion criteria
 ► Diagnosis of NF1 based on NIH criteria.52
 ► Males and females aged between 7 and 16 years of age 
(inclusive) at time of enrolment.
 ► A full scale IQ≥70 or, if a significant discrepancy is 
present between perceptual reasoning index and 
verbal comprehension, the higher index must be ≥70.
 ► An abnormal Inattentive or Hyperactivity/Impul-
sivity Symptom Scale on the parent-rated Conners 3, 
defined as a T score ≥65.
 ► Baseline performance of one or more SD below 
the population mean on the CPT-II omissions 
subscale and/or the CANTAB SWM task total between-
search error score.
Exclusion criteria
 ► Insufficient English to understand the cognitive 
assessments or comply with the study protocol.
 ► Intracranial symptoms or pathology such as epilepsy, 
hydrocephalus, diagnosed traumatic brain injury or 
progressive intracranial tumours that may impact 
cognitive and behavioural function (children with 
asymptomatic or static lesions will be eligible).
 ► Significant visual and/or hearing problems that, in 
the view of the site principal investigator, significantly 
impact on the validity or reliability of cognitive testing.
 ► Blood pressure measurements (systolic or diastolic) 
≥95th percentile for age, sex and height at screening 
or a diagnosis of hypertension.
 ► An abnormal ECG result at the time of screening 
deemed clinically significant by study physician.
 ► Known contraindication or intolerance to the use of 
stimulant medications.
 ► Use of any investigational drugs within 30 days of 
screening.
 ► The current use of prescription or over-the-counter 
medication to induce sleep.
 ► Unable to swallow capsules.
 ► Pregnancy.
 ► Known past or present substance abuse or dependence, 
including alcohol, as determined by the MINI-Kid.
 ► Presence of any other comorbid psychiatric or psycho-
logical disorder (excluding ADHD, oppositional 
defiant disorder, conduct disorder and pervasive 
development disorder/autism spectrum disorder) 
including depressive disorder, anxiety disorder, 
psychotic disorder, suicidality, Tic disorder, anorexia 
or bulimia nervosa.
 ► Treatment with MPH or any other stimulant medica-
tion in the past 21 days.
Randomisation and blinding
Eligible participants will be randomised into either 
sequence A (MPH followed by placebo) or sequence 
B (placebo followed by MPH). Randomisation will be 
managed by an independent statistician at CHW. Rando-
misation will be performed using computer-generated 
random number allocation tables based on a 1:1 allocation 
between groups. Randomisation codes will be maintained 
in a password-protected file and shared with the clinical 
trial pharmacy at each site. The clinical trial pharmacy will 
present the MPH and placebo capsules in plain bottles 
that do not contain treatment allocation. The clinical 
trial coordinator will collect the treatment and distribute 
to the participant. Participants, study physicians, clinical 
trial coordinators, researchers and investigators will be 
blind to treatment allocation. The password-protected 
randomisation allocation file will only be accessible in 
an event where unblinding is deemed necessary, such as 
developing a concurrent medical condition that might 
preclude or contraindicate the administration of MPH.
Intervention
The active treatment is MPH, a central nervous system 
stimulant. MPH is a racemate consisting of a 1:1 mixture 
of d-threo methylphenidate and l-threo methylphenidate. 
Although its mode of action in humans is not completely 
understood, MPH presumably exerts its stimulant effect 
by an inhibition of DA and norepinephrine reuptake, 
primarily in the striatum, and in other regions, such as 
the prefrontal cortex.53 54 New South Wales health guide-
lines indicate the dose of MPH to treat children with 
ADHD should not exceed 60 mg/day and should be no 
more than 2 mg/kg/day. Given the cohort in the current 
study is a new population, we have adopted a maximum 
dose of up to 1.5 mg/kg/day, up to 50 mg/day. Capsules 
are compounded by Stenlake Compounding Pharmacy 
or CHW clinical trial pharmacy using identical methods 
and will contain either 5 mg MPH, 10 mg MPH or inac-
tive lactose powder (placebo). MPH and placebo capsules 
will be indistinguishable and provided to participants as 
crushed powder encased in opaque gelatin capsules.
Titration and dose optimisation
A prescription requesting the number of capsules for the 
titration phase (based on the weight of the participant) 
will be provided to the site pharmacy on enrolment. The 
study coordinator will collect the drug from the site’s clin-
ical trial pharmacy and distribute it to participants.
Treatment dose will be individually determined during 
a titration phase, which will be identical for both placebo 
and MPH conditions. Participants will be provided with 
a titration schedule according to their baseline weight. 
The schedule will include detailed instructions outlining 
the dosage and timing for the titration phase. A member 
of the research team will discuss these instructions with 
the participant’s family to ensure comprehension. Partici-
pants will commence with one capsule administered in the 
morning on day 1 and will slowly escalate to a maximum 
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of three administrations per day to the maximum dose 
allowed for a child’s weight (1.5 mg/kg, ≤50 mg/day). 
Maximum doses are rounded down to the nearest 5 mg. 
Participants will be instructed to swallow the capsules 
whole following food and to take them at the same time 
every day with approximately 4 hours between doses.
The optimal treatment dose will be determined indi-
vidually based on the presence of adverse effects using 
the Side Effects Rating Scale (SERS),55 which is a parent-
rated scale that assesses the frequency and severity of 17 
common adverse effects associated with stimulant medica-
tion from 0 (absent) to 9 (severe). To do this, participants 
and their families will be asked to keep a daily record of 
any adverse effects using a medication diary. During the 
titration phase, study personnel will contact the family 
via telephone at the mid-point (week 1) and end (week 
2) to assess adverse effects using the SERS. If a partici-
pant scores 7 or above on any of the 17 SERS criteria, 
the child’s dose will be reviewed by the site physician. 
The physician will ascertain which day the adverse effect 
first occurred based on the medication diary. The partic-
ipant’s dose will remain at the level at which the adverse 
effect was first experienced. The family will complete 
the SERS again during a follow-up phone call two days 
later. If the adverse effect remains ≥7, then the treatment 
dose will be reduced to the previous dose at which the 
significant adverse effect was not observed. If significant 
adverse effects are not reported at the reduced dose then 
this dose level will be considered the participant’s optimal 
daily dose for the remainder of the treatment period. 
If the significant adverse effects persist on the reduced 
dose, the dose reduction cycle will be repeated until the 
SERS symptom is rated <7.
The SERS will be administered at several time points 
during each treatment condition. The site physician will 
make a clinical judgement on whether there has been 
a significant increase to the existing problem based on 
parent observations and the SERS baseline measurement. 
If deemed a significantly increased adverse effect, the 
dose reduction procedure will apply.
To assess compliance, participants will be required to 
record the time and number of capsules taken in a medi-
cation diary. Unused capsules will be returned at the end 
of each treatment period and the number of returned 
capsules will be recorded.
Once the first treatment condition has been completed, 
participants will cross over to the other treatment on the 
following day. There will be no washout period. The 
procedures for the second treatment condition will be 
identical to those for the first.
Cognitive and behavioural outcomes
The schedule of outcome assessments is detailed in 
figure 2. Primary and secondary outcome measures 
will be administered at baseline (T0/T1) and following 
completion of each 6-week treatment condition (±3 days 
T2, T3). Since MPH is rapidly absorbed56 and the pharma-
codynamics effects mirror the pharmacokinetic profile, 
cognitive outcomes will be administered 45 min after 
treatment dose.57 Parents and teachers will be instructed 
to rate symptom questionnaires based on behaviour over 
the previous 4 weeks.
Primary outcome measures
All primary outcomes capture high basal rates of impair-
ment in NF1.11 12 33 58 59 Cognitive measures are analogous 
to MPH-responsive tests previously used in Nf1 mice,34–36 
assessing sustained attention and spatial working memory. 
The symptom rating scale is standard for ADHD research.
Sustained attention will be measured using the CPT-II: a 
well-established computerised measure with a significant 
history of use in identifying attentional deficits and the 
effects of stimulant medication in research involving indi-
viduals with idiopathic ADHD.60 61 Omission errors will be 
the primary outcome variable from this test.
Spatial working memory will be measured using the 
CANTAB SWM task.47 The SWM task assesses a subject’s 
ability to retain spatial information and to manipulate 
remembered items in working memory. The primary 
outcome variable from this assay will be total between-
search errors.
ADHD symptoms will be measured by the Conners 
3-Parent questionnaire,45 a published and validated tool 
for assessing the presence of inattentive and hyperactive/
impulsive behaviours in children and adolescents. Both 
the Inattentive and Hyperactive/Impulsivity Symptom 
Scales will be used as primary outcomes. Parents will 
be instructed to base their ratings on the participant’s 
behaviour over the previous 4 weeks.
Secondary outcome measures
To understand the potential benefits of MPH on a wider 
range of cognitive and behavioural outcomes, a broader 
battery of tests are included as secondary end points. 
Secondary outcome measures include the Test of Everyday 
Attention for Children (TEA-Ch)62 to measure selective 
attention (Sky Search), sustained attention (Score!), 
divided attention (Sky Search Dual Task) and attentional 
control/switching (Creature Counting): the CANTAB 
Stockings of Cambridge Task and Paired Associate 
Learning Task47 to respectively measure spatial problem 
solving and spatial learning: the Grooved Pegboard63 to 
measure fine motor skills: the Judgement of Line Orienta-
tion (JLO) task64 to measure visuospatial perception and 
orientation and Formulated Sentences from the Clinical 
Evaluation of Language Fundamentals—Fourth Edition 
Australian Version65 to measure expressive language. 
Commission errors from the Conners CPT-II will also be a 
secondary end point of response inhibition.
In addition to the neurocognitive outcomes, a number 
of parent-rated questionnaires will also be administered 
including the Behaviour Rating Inventory of Exec-
utive Function66 as a measure of everyday executive 
behaviour: the Social Skills Improvement System Rating 
Scales67 to evaluate social skills: the Child Behaviour 
Checklist (6–18)68 to assess children's internalising and 
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externalising behaviours and the Paediatric Quality of 
Life Scale 4.0 Generic Core Scales69 to measure health-re-
lated quality of life (both parent and self-report). Where 
possible, the Conners 3 Teacher will also be collected to 
measure ADHD symptoms at school. Secondary outcome 
measures are published assessment tools that are widely 
used in research settings and have standardised instruc-
tions minimising between-site variation. Alternate test 
versions will be administered at the second assessment 
where available (TEA-Ch and JLO).
Neuroimaging outcomes
Neuroimaging will be performed at baseline and at 
the end of both treatment periods (week 6 and week 
12). Imaging will occur within the therapeutic window 
of MPH; approximately 45 min after administration. 
The time of day the participant is scanned (following 
morning, mid-day or afternoon dose) will be consistent 
across assessment visits. Neural correlates of cognitive 
fMRI tasks and the default mode network will be assessed 
after placebo and MPH treatment in children with NF1.
Using event-related MRI procedures, participants will 
perform tasks in the MRI scanner that assess various 
cognitive functions. This will enable us to determine 
the degree to which MPH is able to influence abnormal 
functional neural networks. We will use a well-established 
Auditory Oddball Task to probe the neural correlates of 
selective attention; a Continuous Performance Task to inves-
tigate neural mechanisms of sustained attention and 
working memory and a classic Go-NoGo Task to examine 
the neural process of inhibitory control. The total scan 
time for each paradigm is standardised to 5 min and 8 s. 
Details of the fMRI paradigms have been published,70 
and we have established abnormal NF1-related activation 
in fronto-parietal and fronto-striatal networks using the 
Oddball and Go-NoGo paradigms.20 21
Participants will also undergo a resting state (rs)- fMRI 
sequence lasting approximately 5 min. Participants will 
be instructed to lie in the scanner with their eyes closed 
for the duration of the scan. This sequence will be used 
to identity MPH versus placebo-induced changes in 
Figure 2 Schedule of enrolment, interventions and assessments Standard Protocol Items: Recommendations for Interventional 
Trials figure. 
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functional interactions between neural networks at rest. 
A three-dimensional T1-weighted MRI will be obtained 
from all participants.
Adverse event monitoring
Routine monitoring will occur at screening (T0), week 6 
(T2) and week 12 (T3). Blood pressure, pulse measure-
ments and growth parameters (weight, height) will be 
recorded during monitoring visits. Adverse events (AEs) 
will be collected and recorded at monitoring visits and 
will be based on signs and symptoms reported by the 
participant/parent/caregiver or observed by the investi-
gator during the physical examination. SERS symptoms 
will also be recorded as AEs. Documentation for all AEs 
will include the specific event/condition, the dates and 
times of occurrence, the event severity, duration, likely 
relationship to MPH, action taken and date of resolution. 
Severity of AEs will be graded according to the National 
Cancer Institute’s Common Terminology Criteria for 
Adverse Events (V.3; see table 1). Grade 1 and grade 2 
AEs will be considered non-serious AEs. Grades 3–5 are 
considered serious AEs. If medication is used to treat 
the AE, the dose, route of administration, date and time 
medication is provided, and an indication whether the 
medication will be continued will be required. If a partic-
ipant experiences a grade 2 AE or serious AE which has a 
possible relationship to study drug during any stage of the 
trial, their current dose will be reviewed by the site physi-
cian and may be withheld or modified at the physician’s 
discretion. Any change in dose will be documented.
All serious AEs will be reported to the Human Research 
Ethics Committee that approved the study within 72 hours. 
An independent Data Safety Monitoring Board will eval-
uate all AEs at regular intervals. A project management 
group will meet regularly to monitor the progress of the 
trial. This group will include the Chief Investigator, site 
principal co-investigators and researchers.
sample size
Our study is powered for the primary efficacy analyses. 
Primary outcome measures are SWM between search 
errors (CANTAB), CPT-II omission errors and the Inat-
tention and Hyperactivity/Impulsive Symptom Scales 
from the Conners 3. A previous open-label study, which 
examined the effects of stimulant medication on atten-
tion in children with NF1 using a different continuous 
performance task, reported an effect size of 1.24 for omis-
sion errors following MPH treatment for children with 
NF1.14 Similarly, a previous RCT in children with NF1 
examined the effect of MPH on Conners Parent ADHD 
Rating Scale scores and reported an effect size of Cohen’s 
d=0.96.43 Based on these previous studies in children with 
NF1, we have estimated an effect size of d=0.96, which 
would be classified as a treatment effect of large to very 
large magnitude.71 To detect an effect size of d=0.96 in 
a mixed model crossover design with 80% power and a 
two-tailed significance of 0.05, a total sample size of 36 is 
required.72
statistical analysis
Continuous outcome measures will be analysed using an 
intention-to-treat, mixed-effects linear model. Placebo 
and MPH data points will be compared, adjusted for 
baseline data and any potential carryover effects and clus-
tered at both the individual site level. The mixed model 
allows for more complex within-subject correlation struc-
tures, and accommodates missing and unbalanced data 
between randomisation sequences. Therefore, within this 
model, it is not necessary to impute values for missing 
data. Effect sizes will be calculated as the mean difference 
between MPH and placebo divided by the SD of the differ-
ences (presented as Cohen’s d). All secondary outcome 
measures will be analysed using the same technique.
Patient and public involvement
Neither patient nor the public were involved in the devel-
opment of the research questions, selection of outcome 
measures, study design or study conduct.
EthICs And dIssEMInAtIon
Ethical considerations
This clinical trial has been approved by the Human 
Research Ethics Committee of the Sydney Children's 
Hospitals Network (HREC16/SCHN/261). Governance 
approval of local ethics has been obtained at both study 
sites. Any protocol modifications will be communi-
cated to the study team, ethics committees and the trial 
registry. The study will be conducted in compliance 
with the guidelines for Good Clinical Practice and the 
Declaration of Helsinki and the National Health and 
Medical Research Committee National Statement on 
Ethical Conduct in Human Research. Written informed 
consent will be obtained from all participants before 
participation. During the informed consent process, 
a member of the research team will provide informa-
tion about trial including but not limited to the study 
objectives, potential risks and benefits, inconveniences 
and the participants’ rights and responsibilities. Any 
questions about the trial will be addressed in detail. 
As participants are minors, written informed consent 
will be obtained from their parent/legal guardian. In 
Table 1 Categorisation of adverse effects
Grade Description
1 Mild or asymptomatic, without requiring 
intervention
2 Moderate, requiring minimal or non-invasive 
intervention
3 Severe/medically significant, not immediately 
life threatening but involves hospitalisation or 
prolongation of hospitalisation
4 Life threatening, urgent intervention indicated
5 Death
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addition, a child-friendly written information sheet 
will be provided and verbal agreement for participa-
tion will be obtained from the child. Participation 
will only proceed if the child or adolescent agrees to 
participate in the research. This trial is registered with 
the Australian and New Zealand Clinical Trial Register 
(ACTRN12611000765921).
data management and confidentiality
Data management will be coordinated from The Chil-
dren’s Hospital at Westmead and entered into the 
study database. Quality control will be implemented, 
including checks for double data entry and using range 
checks data values. All data will be anonymised and 
stored by secure means. All paper charts, forms and 
information associated with the study will be kept in a 
locked cabinet in lockable offices at each site’s build-
ings which have swipe access and security presence. All 
participants will be assigned a unique ID that will be 
used throughout the study. All data stored in computer 
systems will be password protected and stored using 
the participants' ID. A list of participant names and IDs 
will be kept separately on the password-protected prin-
cipal investigator's computer. Members of the research 
team involved in the analysis will have full access to the 
de-identified final study dataset.
dissemination
The results of this trial will be submitted for publication 
in peer-reviewed journals and the key findings presented 
at national and international conferences. Members 
of the study team will also disseminate study results at 
patient seminars and parent groups. The investigator 
team will write all articles submitted for peer-reviewed 
publications and authorship inclusion and order will be 
guided by levels of contribution.
discussion
Preclinical trials suggest that DA-targeted therapies, 
such as MPH, may be useful treatments for children 
with NF1-associated cognitive abnormalities. To date, 
previous studies have reported a beneficial effect of 
MPH on ADHD symptoms in children with NF1,14 43 
and the one trial that examined the effects of MPH 
on child-direct assessments, suggested a robust treat-
ment response for attention over a 12-month period.14 
To our knowledge, this is the first RCT evaluating the 
effects of MPH on cognition in NF1 and will provide 
important evidence for the efficacy of MPH in treating 
deficits in attention, working memory and ADHD symp-
toms in children with NF1 over a 6-week period. Open-
label extension studies will be required to determine 
long-term effects of more distal outcomes such as social 
functioning, academic achievement and psychiatric 
comorbidities.
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